<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39392292</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1827-1669</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Minerva medica</Title><ISOAbbreviation>Minerva Med</ISOAbbreviation></Journal><ArticleTitle>BNT162b2 vaccine booster dose did not influence the activity of the exudative form of age-related macular degeneration during anti-vascular endothelial growth factor therapy.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.23736/S0026-4806.24.09379-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Due to safety concerns, patients were hesitant to receive a booster dose of COVID-19 vaccine. In this study, we investigated whether neovascular age-related macular degeneration activity deteriorated after receiving the booster dose of the BNT162b2 vaccine.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Optical coherence tomography (OCT) of the macula, best-corrected visual acuity (BCVA), and slit-lamp examination data were collected from 89 patients. All these individuals were diagnosed with neovascular age-related macular degeneration (AMD) and treated with intravitreal injections of aflibercept or ranibizumab. During the process of treatment, patients received a booster dose of the BNT162b2 vaccine. Time points included two visits before (marked as "-2", "-1") and two visits after (marked as "1", "2") the uptake of the booster dose.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were significant differences in the average thickness and total volume of the macula during follow-up. Moreover, a decreased average thickness, total volume, total thickness of the macula, subretinal fluid thickness, and subretinal complex thickness was observed between the time points "-2" and "2", but only in the aflibercept group. There were no significant differences in the frequency of occurring intraretinal cysts, subretinal fluid, serous retinal pigment epithelial detachments retinal hemorrhage, subretinal hyperreflective material, complete RPE and outer retinal atrophy, and BCVA before and after the booster dose.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results demonstrate that the BNT162b2 vaccine booster dose did not deteriorate the course of neovascular AMD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Płatkowska-Adamska</LastName><ForeName>Bernadetta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Medical and Health Sciences, Collegium Medicum, Jan Kochanowski University, Kielce, Poland - bernadetta.platkowska@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, John Boni Fratres Lodziensis, Łódź, Poland - bernadetta.platkowska@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bociek</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical and Health Sciences, Collegium Medicum, Jan Kochanowski University, Kielce, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kal</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical and Health Sciences, Collegium Medicum, Jan Kochanowski University, Kielce, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ophthalmology Clinic, Voivodeship Hospital, Kielce, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zarębska-Michaluk</LastName><ForeName>Dorota</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Medical and Health Sciences, Collegium Medicum, Jan Kochanowski University, Kielce, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Disease, Voivodeship Hospital, Kielce, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odrobina</LastName><ForeName>Dominik</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Medical and Health Sciences, Collegium Medicum, Jan Kochanowski University, Kielce, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, John Boni Fratres Lodziensis, Łódź, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Minerva Med</MedlineTA><NlmUniqueID>0400732</NlmUniqueID><ISSNLinking>0026-4806</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>8</Hour><Minute>47</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39392292</ArticleId><ArticleId IdType="doi">10.23736/S0026-4806.24.09379-0</ArticleId><ArticleId IdType="pii">S0026-4806.24.09379-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle>